Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Clinical and economic impact of ibalizumab

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Feb 03, 2021 4:18am

101 Views

Post# 32455605

RE:RE:RE:RE:RE:RE:Clinical and economic impact of ibalizumab

If you put 4147 and search you get the numbers under operating revenues, please let me know if you don't see them I try to copy and paste them and post it here.

Wino115 wrote: Not sure where to look. Is that Taimed global unit sales or just to North America & Europe?

scarlet1967 wrote: You are welcome the ticker is 4147 and site is https://emops.twse.com.tw/server-java/t58query.

Wino115 wrote: Thanks Scarlet - I guess I've missed something, but where do you get those granular monthly unit volumes? Is that the Bloomberg data, IVIQ or. from an analyst or Taimed? I've stopped analyzing the monthly's but have to admit they did a pretty good job through this massive healthcare crisis. A little bumpy still, but commendable under the circumstances. I guess it shows one benefit from being a life saving drug.

scarlet1967 wrote: Correct myself the average is the average regardless of big or small orders, Whish is about 58000 units per month for the last 13 months.

scarlet1967 wrote: It was posted earlier but thank you for being a proactive investor looking for news.
As per Trogarzo units orders in the last 13 months THTX placed a total orders summing up to 763801 units with an average monthly units of 58000.
As per January 2021 the last order was about 42000 units and in December 2020 they ordered little over 40000 which is below the average but in the 2020 THTX due to the pandemic placed a couple of big orders for instance in March the biggest order was 119016 units followed by couple of months of well over 65000 units and in July the placed their second biggest order in the last 13 months well over 95000 units I guess they wanted to fill the inventory in case of covid19 related manufacturing issues would cause supply problems.
So we are looking at above 60000 units per month taking those big orders in the equation.
Mesning despite filling the inventory early in the process they are still placing orders..,,,

Saurus100 wrote: Here is a report on Ibalizumab...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066538/#!po=0.724638